Cabot Corporation $CBT Shares Acquired by Paradiem LLC

Paradiem LLC lifted its stake in shares of Cabot Corporation (NYSE:CBT) by 65.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 149,097 shares of the specialty chemicals company’s stock after acquiring an additional 59,030 shares during the quarter. Cabot accounts for about 2.6% of Paradiem LLC’s portfolio, making the stock its 24th largest position. Paradiem LLC’s holdings in Cabot were worth $11,339,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Elevation Point Wealth Partners LLC acquired a new position in Cabot during the 2nd quarter worth $28,000. Parkside Financial Bank & Trust boosted its stake in shares of Cabot by 95.5% in the 2nd quarter. Parkside Financial Bank & Trust now owns 387 shares of the specialty chemicals company’s stock valued at $29,000 after buying an additional 189 shares during the period. Geneos Wealth Management Inc. grew its position in shares of Cabot by 409.0% during the first quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock worth $38,000 after buying an additional 364 shares in the last quarter. UMB Bank n.a. grew its position in shares of Cabot by 52.4% during the second quarter. UMB Bank n.a. now owns 730 shares of the specialty chemicals company’s stock worth $55,000 after buying an additional 251 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Cabot by 344.3% during the second quarter. EverSource Wealth Advisors LLC now owns 813 shares of the specialty chemicals company’s stock worth $61,000 after buying an additional 630 shares during the period. 93.18% of the stock is currently owned by hedge funds and other institutional investors.

Cabot Price Performance

Shares of CBT opened at $66.54 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.61 and a quick ratio of 1.08. Cabot Corporation has a 1-year low of $58.33 and a 1-year high of $93.24. The stock has a market cap of $3.52 billion, a PE ratio of 11.07, a price-to-earnings-growth ratio of 3.48 and a beta of 0.90. The firm has a fifty day moving average price of $65.17 and a 200 day moving average price of $72.67.

Cabot (NYSE:CBT) last issued its quarterly earnings data on Monday, November 3rd. The specialty chemicals company reported $1.70 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.72 by ($0.02). Cabot had a return on equity of 24.55% and a net margin of 8.91%.The firm had revenue of $899.00 million for the quarter, compared to analysts’ expectations of $967.02 million. During the same period in the previous year, the business posted $1.80 EPS. The business’s revenue for the quarter was down 10.2% compared to the same quarter last year. Cabot has set its FY 2026 guidance at 6.000-7.00 EPS. As a group, sell-side analysts anticipate that Cabot Corporation will post 7.57 EPS for the current year.

Cabot Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, December 12th. Shareholders of record on Friday, November 28th were given a dividend of $0.45 per share. The ex-dividend date of this dividend was Friday, November 28th. This represents a $1.80 annualized dividend and a yield of 2.7%. Cabot’s payout ratio is 29.95%.

Analyst Ratings Changes

Several research firms have commented on CBT. Weiss Ratings reiterated a “hold (c-)” rating on shares of Cabot in a report on Monday, December 22nd. JPMorgan Chase & Co. decreased their price objective on shares of Cabot from $75.00 to $54.00 and set an “underweight” rating for the company in a research report on Friday, November 28th. UBS Group dropped their target price on Cabot from $82.00 to $65.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. Zacks Research cut Cabot from a “hold” rating to a “strong sell” rating in a research note on Friday, November 7th. Finally, Mizuho upped their price objective on Cabot from $72.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, December 18th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $66.33.

About Cabot

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.